FourThought Financial’s Alexion Pharmaceuticals ALXN Stock Holding History

FourThought Financial’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-18,093	Closed	-$3.32M	–	1608
2021 Q2	$3.32M	Buy	18,093 +6,378	+54%	+$1.09M	0.44%	53
2021 Q1	$1.79M	Buy	11,715 +232	+2%	+$35.9K	0.26%	75
2020 Q4	$1.79M	Buy	+11,483	New	+$1.48M	0.29%	68

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

FourThought Financial's ALXN Position: Q3 2021 in Review

FourThought Financial sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 18,093 shares — an estimated $3.32M sold.

FourThought Financial first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $3.32M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

FourThought Financial reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
FourThought Financial sold 18,093 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3.32M.
FourThought Financial first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
FourThought Financial's Alexion Pharmaceuticals position peaked at $3.32M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on FourThought Financial's 13F filing for Q3 2021, filed 12 Nov 2021.